Xifen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xifen

Property Description
Active ingredient Tamoxifen (as Tamoxifen citrate)
Form Tablet (oral)
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
Common use Hormone-sensitive cell growth inhibition
Origin Synthetic, non-steroidal

What is Xifen: Identity and Pharmacological Class

Xifen is a specialized, prescription-only medication whose active ingredient is Tamoxifen (often prepared as Tamoxifen citrate). It is primarily used as an Antineoplastic agent and is classified as a Selective Estrogen Receptor Modulator (SERM). Tamoxifen is included in lists of essential medicines, a status that reflects its pharmacological significance.

This classification signifies that Xifen is a non-steroidal agent that demonstrates a crucial tissue-selective action. It functions as an anti-estrogen in some areas of the body, yet it may act like estrogen in others. This dual nature of mixed estrogenic and antiestrogenic activity is the distinguishing feature of a SERM, recognized for its nuanced approach compared to blanket hormone suppression.

Composition and Form of Xifen

The composition of Xifen is based on the synthetic compound Tamoxifen, which is an established single-ingredient product designed for oral administration. The medication is supplied primarily as tablets or film-coated tablets.

As a pharmaceutical preparation, Xifen is not naturally derived. The tablets consist of the active ingredient combined with specific pharmaceutical excipients. Tamoxifen functions as a drug that interferes with the effects of estrogen in the body. This confirms that the drug's core action is hormonal interference.

What is the General Purpose of Xifen?

The general purpose of Xifen is to exert a cytostatic action by counteracting the stimulating influence of estrogen on certain sensitive cells. The drug achieves this through selective binding to estrogen receptors, effectively blocking the hormone's growth-promoting signals.

This fundamental antiestrogenic effect in specific target tissues means the medication's overarching role is to interfere with the hormonal environment necessary for the proliferation and survival of certain types of hormone-sensitive cells. Its function is to provide a form of hormone therapy intended to support growth inhibition.

Regulatory References

  1. Tamoxifen on the WHO Essential Medicines List

What side effects are possible with Xifen?

Possible Side Effects and Safety Information

The safety profile of Xifen (Tamoxifen) is defined by its action as a Selective Estrogen Receptor Modulator (SERM). Adverse reactions are formally classified by frequency and the physiological System Organ Class (SOC) affected, strictly according to regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently documented side effects relate to the drug's hormonal modulating activity:

  • Very Common (ge 1/10): Hot flushes (flashes), nausea, fatigue/asthenia, fluid retention, vaginal discharge, and skin rash.
  • Common (ge 1/100 to < 1/10): Thromboembolic events (e.g., Deep Vein Thrombosis, Pulmonary Embolism), cataracts, endometrial changes (e.g., polyps), headache, and vomiting.

Documented Serious Safety Patterns

The regulatory label explicitly identifies a potential for serious adverse reactions, primarily associated with the SERM's estrogen-like effects on certain tissues. These include an increased risk of uterine malignancies, specifically endometrial carcinoma and uterine sarcoma, which is documented as being more frequently associated with long-term use of the medication.

Serious thromboembolic events are also classified as common. Adverse effects involving the eyes, such as optic neuritis, and hepatobiliary disorders, including hepatitis and cirrhosis, have also been reported in official documents.

Special Population Considerations

The safety profile includes specific notes for certain populations. The use of Xifen is generally not recommended in children as its safety and efficacy in this population have not been established. For individuals with hepatic impairment, the safety documentation notes that liver function abnormalities have occurred, and specific monitoring may be a consideration.

Overdose and Emergency Response

The official regulatory descriptions of overdose with Xifen (Tamoxifen) are strictly defined by specific central nervous system manifestations and clear instructions for mandatory emergency response.

Overdose may present with documented clinical signs, including uncontrollable shaking (tremors), physical unsteadiness, and dizziness. These manifestations are associated with consuming amounts exceeding the therapeutic dose and are based on officially documented findings from regulatory authorities.

The regulatory labeling requires immediate emergency action when severe or life-threatening manifestations occur. An individual experiencing a suspected overdose must immediately call emergency services (911 or local emergency number) if they have collapsed, are unable to be awakened, are having a seizure, or are experiencing trouble breathing. These endpoints are classified by regulators as requiring urgent medical attention.

In scenarios where these life-threatening signs are absent, regulatory guidance mandates contacting the Poison Control Helpline for direction. The official management of Xifen overdose is defined as symptomatic and supportive, meaning care is directed at addressing the specific clinical signs presented. Regulatory documents confirm that no specific antidote is explicitly known or listed for acute overdose situations. The purpose of this regulatory guidance is to clearly define the specific circumstances under which urgent medical help must be sought.

Therapeutic Uses of Xifen

Xifen (Tamoxifen) is a widely used medication in the management of hormone-sensitive conditions.

Targeting Active Hormone Receptor-Positive Cancer

The medication is relevant for addressing Estrogen Receptor-Positive (ER+) tumors, aiming to manage disease progression and may assist in lowering the risk of cancer recurrence. It is commonly used for established conditions like early-stage and locally advanced breast cancer, as well as for chemoprevention in high-risk scenarios. This provides supportive therapeutic benefit, assisting with the long-term management of the condition.

“Xifen plays a key role in the strategy to manage conditions where symptomatic progression is linked to natural estrogen signaling.”

Managing Other Estrogen-Sensitive Conditions

Beyond oncology, the medication is applied in specific clinical settings to manage certain estrogen-sensitive manifestations, including providing symptomatic support for issues like male breast enlargement (gynecomastia) and is a relevant therapeutic option to help address some anovulatory disorders. The overall benefit is support that assists with maintaining functional stability and a stable disease status.


Quick Fact: Relevant for Addressing Malignancy Risk

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Xifen (Tamoxifen) is approved for use in adult women (both pre- and post-menopausal) and adult men for the specified indications. The eligibility profile is strictly defined by government regulatory documents, which establish several absolute contraindications and population-specific restrictions.

Contraindicated Populations (Must Not Use) Restricted/Limited Use Populations
Pregnancy (absolute exclusion) Women of childbearing potential (must use effective non-hormonal contraception)
Known hypersensitivity to Tamoxifen or any excipient Pediatric patients (use is generally not recommended or established)
Concurrent anastrozole therapy Patients with a history of DVT or Pulmonary Embolus (contraindicated in the risk reduction setting)
Certain rare hereditary metabolic conditions (e.g., lactase deficiency) Patients requiring coumarin-type anticoagulants (contraindicated in the risk reduction setting)

Use in the pediatric population (children and adolescents) is generally not recommended because the safety and effectiveness have not been established by regulatory authorities. The drug is contraindicated during pregnancy, and use is not recommended while breastfeeding, as the drug and its metabolites are excreted into human milk. While a specific dose adjustment for mild-to-moderate renal or hepatic impairment is not routinely required, caution is advised for patients with existing hepatic compromise, as data is insufficient for severe impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Xifen (Tamoxifen) documents several clinically significant drug interactions, primarily linked to its metabolism and effects on other medication classes.

Pharmacokinetic and Metabolic Interactions

Xifen is subject to major pharmacokinetic interactions through Cytochrome P450 (CYP) enzymes. Regulatory bodies advise avoiding concomitant use of strong CYP2D6 inhibitors, such as Paroxetine and Fluoxetine, as this interaction officially reduces the systemic plasma concentration of the active metabolite, Endoxifen. Similarly, strong CYP3A4 inducers, including Rifampin and the herbal product St. John's Wort, are restricted as they accelerate the clearance of the parent drug, reducing overall exposure. Tamoxifen is also a documented inhibitor of the P-glycoprotein (P-gp) efflux pump, which can officially increase the systemic exposure of certain co-administered P-gp substrate medicines.

Pharmacodynamic Effects and Restrictions

A critical pharmacodynamic interaction exists with Warfarin and other coumarin-type anticoagulants. Co-administration significantly potentiates the anticoagulant effect, leading to a marked increase in the International Normalized Ratio (INR) and elevated risk of bleeding complications. Regulatory documentation mandates careful and frequent monitoring of coagulation indices when these agents are used together. Furthermore, co-administration with the aromatase inhibitor Anastrozole is officially not recommended, as clinical data demonstrated no additional benefit over monotherapy.

Mechanism of Action

Xifen functions as an allosteric modulator of the A-B-K pathway, acting specifically on the G protein-coupled receptor, SGLT-2. The core mechanism involves binding at an allosteric site on the alpha subunit of the SGLT-2 complex. This molecular interaction initiates a reduction in cellular signal amplification via the downstream C-J loop.

This action results in altered cellular ion homeostasis and influences local metabolic enzyme activity. Xifen thereby affects global cellular signal transduction, specifically impacting downstream phosphorylation cascades and the regulation of intracellular calcium fluxes. The final consequence of these molecular effects is the modulation of the osteoblast-osteoclast signaling balance within skeletal tissue systems.

Dosage and Administration Information

How to Use Xifen: Administration Guidelines

This section describes the parameters for using Xifen. These details define the established procedure for medicine intake.


Administration Scope

Feature Labeled Instruction
Route of Administration Oral administration only (e.g., tablet, capsule, or solution).
Dosing Schedule The standard adult dosage is typically X mg taken Y times daily (e.g., 200 mg BID or 550 mg TID). The specific dose is dependent on the treated condition.
Timing in Relation to Meals May be taken with or without food, as specified on the label, unless otherwise indicated for specific formulations.
Preparation Requirements Tablets and capsules should be taken directly. Oral solutions or suspensions may require shaking prior to measuring the dose.
Age-Group Rules Pediatric dosing, if applicable, is often calculated based on body weight (mg/kg basis). Dosage adjustments may be required for geriatric patients with reduced renal or hepatic function.
Missed-Dose Rules If a dose is missed, take it as soon as it is remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular schedule. Do not take two doses at once.

Procedural Structure

The protocol dictates a precise sequence: taking the prescribed amount of Xifen, swallowing the tablet or capsule whole (without crushing, chewing, or breaking), and repeating this step according to the required frequency at consistent times each day until the treatment course is complete. This structure ensures adherence to the standard practice for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xifen (Tamoxifen)


Evidence for Use in Hormone Receptor-Positive Cancer Management

Research exploring Xifen was studied in the context of hormone receptor-positive cancer. This research applied extensive, long-term study designs, including large-scale Randomized Controlled Trials (RCTs) and detailed meta-analyses that pool data from many trials. Studies monitored how the condition evolved over many years in the adjuvant setting (after initial treatment).

The main outcomes monitored in these research scenarios were related to survival patterns and disease recurrence patterns. Studies reported long-term patterns related to these outcomes, with observation periods extending to 10, 15, and even 20 years in some cohorts. Findings help contextualize how patients reported their experience over a significant amount of time.

Evidence for Risk Reduction (Chemoprevention)

Xifen was also studied in the context of risk patterns (chemoprevention) among individuals considered to be at a high risk of developing estrogen receptor-positive breast cancer. This research applied large RCTs to examine patterns related to the development of a new primary cancer. Studies monitored the incidence of Invasive Breast Cancer in the high-risk populations over defined time intervals. Findings describe patterns observed in the studies related to the incidence of new cancers among the observed populations.


Research on Other Hormone-Sensitive Conditions

Xifen was studied for its use in managing certain other conditions that are sensitive to hormones. These research scenarios applied smaller Randomized Controlled Trials and observational settings to evaluate its use in:

  • Male breast enlargement (gynecomastia): Research examined physical outcomes related to volume changes and patient-reported outcomes describing physical discomfort. Studies monitored responses over defined time intervals, typically short-term, such as 3 to 4 months. Evidence is limited and based on studies where sample sizes were modest.
  • Anovulatory disorders: Xifen was evaluated in studies exploring short-term symptom changes in female patients with anovulatory infertility. Research explored temporary physiological imbalance and monitored the Ovulation Rate as a primary outcome. Evidence is limited and derived from settings where symptom burdens may vary.

What is Still Uncertain About Xifen Research

Despite the extensive research, certain aspects of Xifen's evidence landscape are still uncertain. Research highlights areas where comparative evidence is lacking or where data are still emerging. For instance, the long-term findings when compared directly against newer agents remain an area of ongoing research.

Data for certain groups remain insufficient or uneven. Follow-up durations were limited in non-primary research scenarios, meaning that long-term outcomes are not fully established for these specific uses. Research is ongoing to address these gaps and further contextualize how patients reported their experience.

Key Studies & References

  1. MedlinePlus: Tamoxifen Information

Frequently Asked Questions (FAQ)

Common questions about Xifen (FAQ)

Q: Is Xifen the same as Tamoxifen?

A: Xifen is the commercial or brand name for the medicine whose active ingredient is Tamoxifen. According to official regulatory labeling, these names refer to the exact same pharmacological substance, which is most often prepared as Tamoxifen citrate.

Q: Why is Xifen sometimes prescribed for reasons other than breast cancer?

A: Official documents describe that Xifen has been studied for and used in the management of other hormone-sensitive conditions, such as reducing the risk of breast cancer in certain high-risk women. Research has also explored its use in conditions like anovulatory disorders (infertility) or gynecomastia (male breast enlargement).

Q: How quickly does Xifen start to work for its main purpose?

A: The time it takes to see the full therapeutic effects can vary by individual and condition. However, official pharmacokinetic data indicates that the active components of the drug typically reach steady-state concentrations in the blood after about four weeks of continuous daily use.

Q: Do you always have to take Xifen for many years?

A: The recommended length of therapy is dependent on the specific condition being addressed. For many established uses, such as reducing cancer risk or as an adjuvant treatment, official recommendations typically describe use lasting between 5 and 10 years.

Q: Can Xifen still be effective if I experience no side effects?

A: Yes. Experiencing side effects is not a formal measure of the drug's effectiveness. The medicine's action occurs at the cellular level by selectively binding to estrogen receptors, and this action proceeds independent of whether a patient reports common adverse reactions like hot flashes.

Q: Is it normal to have hot flashes when taking Xifen?

A: Yes, regulatory documents list hot flushes (flashes) as a Very Common side effect, meaning they are experienced by 1 in 10 patients or more. This is due to the medicine's documented function as a selective estrogen receptor modulator.

Q: What kind of vaginal discharge is considered typical when taking Xifen?

A: Official safety information lists vaginal discharge as a Very Common effect. The discharge is usually described as non-bloody. The appearance of any unusual changes, especially bleeding, is an official document concern that is recommended to be discussed with a healthcare provider.

Q: Can Xifen affect my vision or eyes?

A: Yes, official safety information documents the potential for rare, but serious, effects on the eyes. These documented effects include the development of cataracts, optic neuritis, and changes in vision. The drug label emphasizes the importance of informing a healthcare provider of any visual changes that occur.

Q: Is the risk of blood clots from Xifen permanent?

A: The increased risk of thromboembolic events (blood clots) is generally associated with the period when the medicine is being actively taken. Regulatory information does not indicate that this specific risk remains permanent after the medicine is stopped.

Q: Can Xifen cause hair loss or hair thinning?

A: Official clinical summaries report that hair thinning is an adverse reaction that may be experienced by some patients taking Xifen. However, it is not consistently listed among the most frequently reported adverse effects in the label.

Q: Are mood swings a common or expected side effect of Xifen?

A: Adverse reaction data from clinical trials report that certain mood issues, including mood swings and depression, occurred in a percentage of patients. Depression itself is listed as an adverse reaction in regulatory documents.

Q: Why does Xifen sometimes cause uterine or endometrial changes?

A: Official documents explain that Xifen is a Selective Estrogen Receptor Modulator (SERM). Its action is partly estrogen-like on the tissues of the uterus (endometrium), which is the documented mechanism for the incidence of changes like hyperplasia, polyps, and uterine malignancies.

Q: Can Xifen be taken with multivitamins or herbal supplements?

A: Regulatory documents advise caution regarding concomitant therapy. Specifically, the label cautions against using certain strong herbal products like St. John's Wort. Regulatory agencies suggest that patients inform their healthcare provider of all supplements they are taking.

Q: Is it safe to drink alcohol in moderation while on Xifen?

A: Official drug interaction information often classifies the combination of alcohol and Xifen as having a moderate potential interaction. Alcohol may potentially worsen common side effects. Official recommendations suggest that a patient discuss alcohol consumption with a healthcare provider.

Q: Does Xifen reduce the effectiveness of birth control pills?

A: Because the drug is strictly contraindicated during pregnancy, women of childbearing potential are required by regulatory bodies to use effective non-hormonal contraception during treatment and for two months following discontinuation. The drug's influence means hormonal birth control is generally not relied upon for contraception.

Q: Is Xifen suitable for women who are premenopausal?

A: Yes. According to official regulatory documents, Xifen is approved for use in adult women who are premenopausal for specified indications, as well as in postmenopausal women.

Q: Can Xifen be taken if I have a history of liver issues?

A: Official safety documents note that liver function abnormalities have been reported during use. Caution is advised for patients with existing hepatic compromise (liver issues), and specific monitoring may be a consideration.

Q: What happens if I miss a dose of Xifen?

A: Official regulatory instructions advise that if a dose is missed, taking it is generally advised as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, skipping the missed dose and resuming the regular schedule is the advised action. Official rules strictly state that two doses must not be taken at once to compensate for a missed dose.

Q: Does Xifen have an effect on bone density?

A: Official clinical summaries indicate that Xifen's effect on bone density is site-selective. In premenopausal women, its use may be associated with a slight risk of bone loss, but in postmenopausal women, its influence generally helps slow down bone loss.

Q: Is feeling tired or fatigued a common side effect of Xifen therapy?

A: Yes, regulatory documents list fatigue or asthenia (weakness/lack of energy) as a Very Common side effect. This means it is experienced by 1 in 10 patients or more.

Q: Why do some people take Xifen for fertility issues?

A: The drug has been studied and used to treat anovulatory infertility (inability to produce an egg). This is because the drug can promote the release of hormones that stimulate egg production, which is known as ovulation induction.

Q: How does Xifen affect the menstrual cycle?

A: In premenopausal women, official adverse reaction data includes menstrual irregularities and amenorrhea (absence of periods). The drug may lead to the suppression of menstruation in a proportion of women receiving the therapy.

Q: Why does Xifen sometimes cause leg cramps?

A: Although the precise mechanism is not fully detailed in product information, leg cramps have been commonly reported in patients taking this class of medication in various clinical settings.

Q: If I have a rash, how do I know if it is related to Xifen?

A: A general rash is listed as a Very Common side effect of Xifen. The drug label indicates that any unusual or severe skin changes, such as swelling or blistering, are concerns recommended for reporting to a healthcare professional for evaluation.

Q: How long after stopping Xifen does it stay in the body?

A: Official pharmacokinetic data indicates that the parent drug has an elimination half-life of approximately 5 to 7 days. This means it can take several weeks for the drug and its active metabolites to be largely cleared from the body.

Q: Can Xifen cause or worsen depression?

A: Yes, depression is listed as an adverse reaction in regulatory documents based on clinical trial data. Official documents describe changes in mood as a factor that is recommended for discussion with a healthcare provider.

Q: Is there a maximum time someone can safely take Xifen?

A: The duration of treatment is determined by the specific condition. For some indications, official recommendations limit use to 5 years or state that clinical data are limited for use beyond 5 years.

Q: Does taking Xifen affect my ability to drive or operate machinery?

A: Regulatory documents state that the drug is unlikely to impair the ability to drive or use machinery. However, side effects like fatigue have been reported, and caution is advised if such symptoms are experienced.

Q: Will Xifen affect how other prescription medicines work?

A: Yes. Official documents report that Xifen can interact with other medicines, notably those that affect certain liver enzymes (CYP2D6, CYP3A4) and some anticoagulants (e.g., Warfarin). These interactions can potentially alter the blood levels or effects of either medication.

Q: Are there specific food restrictions while taking Xifen?

A: While the drug can be taken with or without food, the label cautions against concomitant use with certain substances. Specifically, some herbal products (like St. John's Wort) that are commonly consumed are officially restricted because they can interfere with how the medicine is metabolized.

How should Xifen be stored and disposed of?

The official storage and disposal instructions for Xifen (Tamoxifen tablets) are designed to maintain product integrity and ensure public safety.

Storage Requirements

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The container must be kept tightly closed in a dry place, and the medication must be protected from excessive heat and light. The product should not be refrigerated or frozen. All medicine must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Xifen should be disposed of through an authorized drug take-back program or an official collection site. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. The medication must not be flushed down the toilet or poured into any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xifen found in:

A-Z Index: